{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+B&page=2",
    "query": {
      "intervention": "Part B",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+B&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T12:33:48.941Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03351608",
      "title": "Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Neuromuscular Blockade"
      ],
      "interventions": [
        {
          "name": "Sugammadex 2 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Sugammadex 4 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Neostigmine + Glycopyrrolate",
          "type": "DRUG"
        },
        {
          "name": "Neostigmine + Atropine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "2 Years to 16 Years"
      },
      "enrollment_count": 288,
      "start_date": "2018-02-12",
      "completion_date": "2020-01-28",
      "has_results": true,
      "last_update_posted_date": "2021-02-05",
      "last_synced_at": "2026-09-03T12:33:48.941Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Palo Alto, California • San Diego, California + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03351608"
    },
    {
      "nct_id": "NCT04558346",
      "title": "Ghrelin (OXE--103) for Acute Concussion Management",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Concussion, Brain",
        "Traumatic Brain Injury"
      ],
      "interventions": [
        {
          "name": "Ghrelin (OXE-103)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Michael Rippee",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 23,
      "start_date": "2020-10-20",
      "completion_date": "2022-10-30",
      "has_results": true,
      "last_update_posted_date": "2024-05-21",
      "last_synced_at": "2026-09-03T12:33:48.941Z",
      "location_count": 1,
      "location_summary": "Kansas City, Kansas",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04558346"
    },
    {
      "nct_id": "NCT02573597",
      "title": "PIEB vs CEI for Labor Analgesia: An MLAC Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pregnancy"
      ],
      "interventions": [
        {
          "name": "Bupivacaine",
          "type": "DRUG"
        },
        {
          "name": "Sufentanil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 31,
      "start_date": "2015-10",
      "completion_date": "2018-05-22",
      "has_results": true,
      "last_update_posted_date": "2022-10-18",
      "last_synced_at": "2026-09-03T12:33:48.941Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02573597"
    },
    {
      "nct_id": "NCT03429803",
      "title": "DAY101 In Gliomas and Other Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Low-grade Glioma"
      ],
      "interventions": [
        {
          "name": "DAY101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Karen D. Wright, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "1 Year to 25 Years"
      },
      "enrollment_count": 44,
      "start_date": "2018-02-27",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-19",
      "last_synced_at": "2026-09-03T12:33:48.941Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03429803"
    },
    {
      "nct_id": "NCT04470427",
      "title": "A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "SARS-CoV-2"
      ],
      "interventions": [
        {
          "name": "mRNA-1273",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30415,
      "start_date": "2020-07-27",
      "completion_date": "2022-12-29",
      "has_results": true,
      "last_update_posted_date": "2024-03-21",
      "last_synced_at": "2026-09-03T12:33:48.941Z",
      "location_count": 100,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 79 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04470427"
    },
    {
      "nct_id": "NCT06295159",
      "title": "Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma Stage III",
        "Melanoma Stage IV",
        "Advanced Melanoma",
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab + Relatlimab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2024-05-17",
      "completion_date": "2028-11",
      "has_results": false,
      "last_update_posted_date": "2026-04-01",
      "last_synced_at": "2026-09-03T12:33:48.941Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06295159"
    },
    {
      "nct_id": "NCT05121103",
      "title": "A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma, Refractory",
        "Diffuse Large B-Cell Lymphoma",
        "Diffuse Large B Cell Lymphoma Refractory",
        "Multiple Myeloma in Relapse"
      ],
      "interventions": [
        {
          "name": "EZM0414",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Epizyme, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2022-05-31",
      "completion_date": "2024-04-30",
      "has_results": true,
      "last_update_posted_date": "2025-06-22",
      "last_synced_at": "2026-09-03T12:33:48.941Z",
      "location_count": 8,
      "location_summary": "Duarte, California • East Brunswick, New Jersey • New York, New York + 3 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "East Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05121103"
    },
    {
      "nct_id": "NCT00314782",
      "title": "Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "ZD4054 (Zibotentan)",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 44,
      "start_date": "2006-03",
      "completion_date": "2009-03",
      "has_results": false,
      "last_update_posted_date": "2013-03-12",
      "last_synced_at": "2026-09-03T12:33:48.941Z",
      "location_count": 3,
      "location_summary": "Buffalo, New York • Greenville, South Carolina • Nashville, Tennessee",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Greenville",
          "state": "South Carolina"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00314782"
    },
    {
      "nct_id": "NCT03881059",
      "title": "Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Active Psoriatic Arthritis"
      ],
      "interventions": [
        {
          "name": "BMS-986165 Placebo",
          "type": "OTHER"
        },
        {
          "name": "BMS-986165 Dose A",
          "type": "DRUG"
        },
        {
          "name": "BMS-986165 Dose B",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 203,
      "start_date": "2019-04-01",
      "completion_date": "2021-01-27",
      "has_results": true,
      "last_update_posted_date": "2022-02-15",
      "last_synced_at": "2026-09-03T12:33:48.941Z",
      "location_count": 31,
      "location_summary": "Huntsville, Alabama • Covina, California • La Jolla, California + 27 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Covina",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Aventura",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03881059"
    },
    {
      "nct_id": "NCT06617546",
      "title": "SAD and MAD Study of FTX-101 in Healthy Male Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "FTX-101",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Find Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "59 Years",
        "sex": "MALE",
        "summary": "18 Years to 59 Years · Male only"
      },
      "enrollment_count": 49,
      "start_date": "2024-10-14",
      "completion_date": "2025-04-17",
      "has_results": false,
      "last_update_posted_date": "2025-06-18",
      "last_synced_at": "2026-09-03T12:33:48.941Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06617546"
    }
  ]
}